Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PET scan may solve brain tumor puzzle: regrowth or side effect?

NCT ID NCT07238322

Diagnosis Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a special type of PET scan (using a tracer called FET) can accurately tell the difference between a returning brain tumor (glioma) and harmless changes caused by previous treatment. Researchers analyzed scans from 253 patients of all ages who had already been treated for glioma and showed suspicious signs on MRI. The goal was to see if FET-PET could help doctors make better decisions without needing a biopsy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

253 people

The number who actually took part.

Started

Sep 2025

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients who are enrolled in the study will be included in the FAS.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Signed patient informed consent with secondary use of data permitted. Pediatric patients (\<18 years of age) will provide assent along with parental/legal guardian /caregiver consent 2. Male or Female of any age at the time of \[18F\]FET PET imaging. While there is no age restriction, it is expected that enrollment of patients ≤ 3 years old will be rare due to the very low incidence of glioma in this age group. 3. Documented histologic diagnosis or clinical suspicion of glioma (Grades 1-4) based on local clinical assessment. 4. Underwent \[18F\]FET PET imaging as part of routine clinical care after completion of primary treatment (surgery, radiation therapy, and/or chemotherapy). 5. Evidence of radiographic suspicion of recurrence or progression on MRI at the time of \[18F\]FET PET imaging. 6. The adult patient, 18 years of age or older, has received nominal injected dose of 4 to 7 mCi (148 - 259 MBq ) of \[18F\]FET per imaging time point. 7. The pediatric patients, 0-17 years old, must have received a pediatric dose adjusted based upon the patient's body weight. Exclusion Criteria: Participants will be excluded if they did not meet any of the inclusion criteria or institutional requirements for participation. 1. Did not meet all inclusion criteria. 2. Did not undergo \[18F\]FET PET imaging as part of routine clinical care. 3. Imaging data or associated clinical information is incomplete, non-evaluable, or of insufficient quality for analysis. 4. Any institutional or regulatory requirement that precludes data sharing or inclusion in retrospective research studies.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain neoplasms GLIOMA Retrospective study

Contacts and locations

Locations

  • The University Medical Center Utrecht

    Utrecht, Netherlands

  • University Hospital Essen

    Essen, Germany

  • University of California, San Francisco

    San Francisco, California, 94107, United States

  • Universityhospital Tuebingen

    Tübingen, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.